Tatsushi Kawada
@K_Tatsushi
Followers
65
Following
145
Media
1
Statuses
33
泌尿器科＠岡山大学病院 Urologist @Okayama_Uni_Hosp Research fellow @Med_Uni_Wien
Okayama-ken, Japan
Joined April 2020
Editor's Choice: Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial by @nickva1 et al Read the full article here: https://t.co/Q7kqBXv0aJ Come back to read the Editorial! #UroSoMe #MedTwitter
1
30
66
Words have power: to empower, to teach, and to optimize, but also to scare, to confuse, and to withhold👉For our pts with #prostatecancer 👉@PCFnews roundtable team asks to avoid words like “castration,” & adapt the following👇@urotoday @EUplatinum Link👉 https://t.co/bmw6hQE83i
4
46
125
New! This Cheat Sheet on the EAU Guidelines for Renal Transplantation covers donor and recipient complications. Management includes surgical interventions and medical therapies to address risks effectively. #KidneyTransplant #EAUguidelines Download here: https://t.co/EiwNIhotI6
0
19
52
Join us for the 1st Int'l Urologic Cancer Symposium in Tokyo! 8/28, 18:30-20:30 Jikei Uni. Featuring ＠dr_rajwa, @BenjaminPradere & ＠FQuhal. Open to all, including non-institution members!
1
5
15
Outcomes of active surveillance for Japanese patients with #ProstateCancer (PRIAS-JAPAN) https://t.co/ZGYxHRM4RE
0
9
19
📹 Dr. @dr_rajwa talks to Prof. @BertrandTOMBAL and Prof. @Prof_Nick_James about selecting optimal therapy for men with synchronous mHSPC. Discover the currently available treatments & know more about therapy objectives 👇 https://t.co/JKeapNuhMP
#prostatecancer #oncology
prostate.uroonco.uroweb.org
Our associate editor Dr. Rajwa talks to Prof. Tombal and Prof. James on the management of synchronous metastatic hormone sensitive prostate cancer.
1
12
18
Read the new Paper from the #CCCVienna @MedUni_Wien @Uro_MedUniWien @fazekasMD @DrShariat #ProstateCancer #MRI #Oncology #Overdiagnosis #PSA #Biopsies #JAMAOncology #Screening
Integrating MRI in prostate cancer screening pathways reduces the number of unnecessary biopsies and the overdiagnosis of insignificant cancers, while maintaining clinically significant prostate cancer detection as compared with PSA-only screening. https://t.co/zquO7RM7S5
#EAU24
0
2
6
Vienna fellowship friendship dinner 🥳#EAU24 @DrShariat @Uro_MedUniWien @BenjaminPradere @Keiichiro__Mori @dr_rajwa @fazekasMD @FQuhal @PallaufM @nico_grossmann @gehi87 @K_Tatsushi @MarcinChlosta
3
7
57
Press release: Ph3 Splash trial in mCRPC #prostatecancer with Lutetium-177-PSMA-I&T vs. ARPI/NHT switch, meets primary endpoint:⬆️rPFS: 9.5 vs 6 mos, HR 0.71. Lu-177 dose lower than PSMAfore trial with Lu-177-PSMA-617👇Link: https://t.co/wcVFWn2chI
@OncoAlert @urotoday @PCFnews
2
67
127
Hope this study helps the diagnostic strategy for csPCa.@EurUrolOncol
https://t.co/uNbQW06GJi
@FQuhal @dr_rajwa @BenjaminPradere @gehi87 @E_Laukhtina @mvdeimling @DrShariat
euoncology.europeanurology.com
Novel biomarkers for prostate cancer have promising diagnostic performance for detecting clinically significant prostate cancer (csPCa). Based on the optimal thresholds calculated by the present...
0
0
11
Lancetに日本の大学病院の医師の悲惨な研究環境が ・研究時間がない（講師の50％、助教授の65％が週に5時間未満。助教授の15％は0時間。） ・34％の医師が過労死ラインの年960時間以上で勤務 →大学病院の診療で食っていけて、研究できるようにしないと日本は益々衰退する https://t.co/2E0p5CvQuA
thelancet.com
The decline in Japan's research capabilities has been a long-standing issue, particularly in the medical field. Several public surveys have revealed the seriousness of the situation.1,2
9
390
1K
Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer—Evidence from Recent Prospective Reports https://t.co/I03pcFsmeS
@dr_rajwa @Fabio_Zattoni @M_MaggiMD @GMarra_MD @DrShariat @Albert0Briganti @F_Montorsi @GGandaglia
#prostatecancer
0
15
39
📹 How does #FGFR screening assist in bladder-sparing treatment? This is the core topic of discussion between pathologist Assoc. Prof. @AlessiaCim & UROONCO BCa chief editor Dr. @BenjaminPradere. Learn about their insights. Watch the interview now 👇 https://t.co/7hsI4VdLhi
bladder.uroonco.uroweb.org
0
5
14
#systematicreview #metaanalysis 🙏 A collaborative work with @USC_Urology 💥Interplay between Radical Cystectomy and Renal Function 📰 https://t.co/NEY3PC4P53
@alirezaghoreifi @gehi87 @K_Tatsushi @siadaneshmand @Hoomandjaladat @DrShariat
0
7
23
Our findings suggest that worse PS should not discourage treatment intensification across all PCa stages. @BJUIjournal @gehi87 @DrShariat @FQuhal @E_Laukhtina @BenjaminPradere @Uro_MedUniWien
https://t.co/9aJuM1ITyu
0
9
23
🚨Preliminary results of the SUNRISE-1 🌅 study using TAR-200 🥨 (Gemcitabin) @siadaneshmand ➡️in BCG unresponsive ✨Promising results ✨ 👉 72.7% of overall CR with TAR-200 👉cetrelimab does % (similar to Pembro KN057) Gem is a great drug #AUA23
0
15
42
The current role of precision surgery in oligometastatic #ProstateCancer. #BeyondTheAbstract with @mvdeimling and @DrShariat. #ReadNow on UroToday > https://t.co/RzivwcbnUX
@UKEHamburg @Uro_MedUniWien
0
2
5
The current role of precision surgery in oligometastatic #ProstateCancer. #BeyondTheAbstract with @mvdeimling and @DrShariat. #ReadNow on UroToday > https://t.co/RzivwcbnUX
@UKEHamburg @Uro_MedUniWien
0
2
6
The current role of precision surgery in oligometastatic #ProstateCancer. #BeyondTheAbstract with @mvdeimling and @DrShariat. #ReadNow on UroToday > https://t.co/RzivwcbnUX
@UKEHamburg @Uro_MedUniWien
1
6
8
Prostate cancer risk, screening, and management in patients with germline BRCA1/2 mutations @NatRevUrol @DrShariat @gpalapa2 @Albert0Briganti @wandering_gu @amerseburger @Tilki_De @gorejohn @mleapman @GPloussard @GGandaglia @BenjaminPradere @FQuhal
https://t.co/LNt63xaGps
1
41
116